Price as of close on Nov 3, 2026 · Financials updated Oct 10, 2026
Basics
Sector
Healthcare
Industry
Health Information Services
Country
United States
Market cap
532.4M USD
Enterprise value
536.4M USD
Full-time employees
357
Overall health
Strength:more profitable than most peersmore profitable than peers
Drawback:growing more slowly than most peersgrowing more slowly than peers
Drawback:higher risk than most peers: less short-term liquidity (current ratio 0.65 vs a peer median of 2.59) and more debt relative to equity (14.36× vs a peer median of 0.22×)higher risk: less liquidity (current ratio 0.65 vs peers 2.59) and more debt vs equity (14.36× vs peers 0.22×)
About average: valuation
Ranks #916 of 1,157 healthcare companies (bottom 21%)
Returning more cash than it generates. Paid out $129M vs $57M of free cash flow over the 3 fiscal years to 2025.
NRC Health returned $129M to shareholders over three years, 225% of the free cash flow it produced. That gap has to be covered by cash reserves or new debt, which can't last indefinitely.
Much more borrowing than peers.Debt is 14.4× equity vs a peer median of 0.2×.Debt is 14.4× equity vs peers 0.2×.
Debt is 14.4× shareholders' equity, against a peer median of 0.2×, among the highest 10% of its peer group.Debt is 14.4× shareholders' equity, vs peers 0.2×, among the highest 10% of its peer group.
Operating margin at a 6-year low.16% in 2025, the weakest of the last 6 years.
NRC Health's operating margin fell to 16% in 2025, its lowest in the 6 years of filings we have.
Borrowing rising faster than profit. Since 2022: debt +195%, operating profit −51%.
NRC Health's debt grew 195% since 2022 while operating profit changed −51%.
Since last quarter: No major changeValuation also moves with the share price every day.
Why it changed since the Oct 27, 2026 close: Score 47 → 46
Share price +10.7%-1
Each step re-scores the company against its peers as they were on Oct 28, 2026; the parts add up to the change. Price effects on EBITDA yield are approximate.
Why it changed since the Oct 27, 2026 close: Safety percentile 8 → 9
Peer companies moved+1
Each step re-scores the company against its peers as they were on Oct 28, 2026; the parts add up to the change. Price effects on EBITDA yield are approximate.
Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.
Questions investors ask about NRC Health
Is NRC Health getting weaker?
Its latest SEC filing (Aug 4, 2026) got weaker in some ways: operating margin fell 3.6 points to 10.5%; debt up 21%. Its overall score is unchanged at 34/100 since Oct 28, 2026.
How is NRC Health valued vs its peers?
Priced about in line with its peers. Valuation scores 46/100 against 1,393 healthcare peers.
Is NRC Health growing?
More slowly than most of its peers. Growth scores 15/100 against 1,393 healthcare peers.Earnings per share growth -65.9% vs a peer median of 9.8% (weaker than 95% of peers).Earnings per share growth -65.9% vs peers 9.8% (weaker than 95% of peers).
How profitable is NRC Health?
More profitable than most of its peers. Profitability scores 67/100 against 1,393 healthcare peers.Return on invested capital 12.0% vs a peer median of 4.7% (stronger than 73% of peers).Return on invested capital 12.0% vs peers 4.7% (stronger than 73% of peers).
How risky is NRC Health?
Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings.Beta 0.28 vs a peer median of 0.63 (stronger than 81% of peers).Beta 0.28 vs peers 0.63 (stronger than 81% of peers).Current ratio 0.65× vs a peer median of 2.59× (weaker than 100% of peers).Current ratio 0.65× vs peers 2.59× (weaker than 100% of peers). A relative measure, not a bankruptcy probability.
Latest filing: what changed
Quarter ended Jun 30, 2026 · filed Aug 4, 2026 · compared with the quarter ended Mar 31, 2026
Got weaker
Operating margin fell 3.6 points to 10.5%
Debt up 21%
Previous quarter
Latest quarter
Change
Revenue (12 months)
138.6M USD
140.0M USD
+1.0%
Net income (12 months)
9.0M USD
5.9M USD
−35.2%
Operating margin
14.1%
10.5%
−3.6 pts
Free cash flow (12 months)
17.4M USD
21.6M USD
+24.2%
Debt
78.0M USD
94.0M USD
+20.5%
Cash
2.5M USD
3.3M USD
+30.6%
Shares outstanding
22.5M
22.1M
−1.9%
From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.
Industry valuation context
Sector: Healthcare · 301 companies
Valuations in Healthcare are within their usual range since 2016.
52% of months since 2016 were valued lower than now.
19% of companies are in the most expensive fifth of their own price-to-sales history.
Over 24 months, company values +8% and earnings +24% (medians): earnings grew faster than prices.
Median price-to-sales is +63% vs the whole market, against a usual +119%.
2016Shaded: most expensive fifth of its range2026
Shown for Healthcare: too few Health Information Services companies have a long enough history of their own.
Earnings-based measures are left out for now because many companies in Healthcare are losing money.
Describes valuations since 2016; it does not predict prices. US companies worth $1B+, from SEC filings and month-end prices, as of Aug 2026. Today's companies and industry labels are used throughout. Measured on sales and free cash flow yields. How this works
Financials
Fiscal years from SEC annual filings · change vs the prior year
Key ratios
FY 2021
FY 2022
FY 2023
FY 2024
FY 2025
Change
Operating margin
34.0%
30.7%
27.0%
24.6%
16.4%
▼ 8.2 pts
Net margin
25.3%
21.0%
20.8%
17.3%
8.4%
▼ 8.9 pts
Return on assets (ROA)
23.8%
24.4%
25.3%
18.7%
8.6%
▼ 10 pts
Return on equity (ROE)
43.9%
44.1%
63.3%
79.2%
82.9%
▲ 3.7 pts
Free cash flow margin
27.6%
17.4%
15.0%
13.4%
11.5%
▼ 1.9 pts
Current ratio
1.82×
1.31×
0.67×
0.55×
0.55×
▲ 1.0%
Debt to equity
0.36×
0.37×
0.90×
2.00×
5.65×
▲ 182%
Interest coverage
30.16×
38.50×
46.46×
13.56×
4.74×
▼ 65%
NRC price history
Price history is added with the daily price update and will appear after the next one.